APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Melatonin Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting Melatonin Receptor Agonists Market Analysis and Forecast 2026-2032

Report ID 174008840220 December 2025191 pages

Choose your research edition.

Industry ResearchLong-acting Melatonin Receptor Agonists Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Melatonin Receptor Agonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Long-acting Melatonin Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Melatonin Receptor Agonists Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Melatonin Receptor Agonists Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Long-acting Melatonin Receptor Agonists market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Long-acting Melatonin Receptor Agonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting Melatonin Receptor Agonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting Melatonin Receptor Agonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting Melatonin Receptor Agonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Long-acting Melatonin Receptor Agonists include Takeda, Sichuan Kelun Pharmaceuticals, Sichuan Guowei Pharmaceuticals, Novartis, Jiangsu Hausen Pharmaceuticals, Hangzhou Lingye Pharmaceutical Technology, Guangdong Annuo Pharmaceuticals, Vanda Pharmaceuticals and Servier Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Long-acting Melatonin Receptor Agonists, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting Melatonin Receptor Agonists, also provides the revenue of main regions and countries. Of the upcoming market potential for Long-acting Melatonin Receptor Agonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting Melatonin Receptor Agonists revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting Melatonin Receptor Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Long-acting Melatonin Receptor Agonists revenue, projected growth trends, production technology, application and end-user industry.

Long-acting Melatonin Receptor Agonists Segment by Company

Takeda

Sichuan Kelun Pharmaceuticals

Sichuan Guowei Pharmaceuticals

Novartis

Jiangsu Hausen Pharmaceuticals

Hangzhou Lingye Pharmaceutical Technology

Guangdong Annuo Pharmaceuticals

Vanda Pharmaceuticals

Servier Laboratories

Rovi Pharma

Nectid Inc

Dr Reddy's Laboratories

Long-acting Melatonin Receptor Agonists Segment by Type

Ramelteon

Agomelatine

Other

Long-acting Melatonin Receptor Agonists Segment by Application

Hospital

Clinic

Other

Long-acting Melatonin Receptor Agonists Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Melatonin Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Melatonin Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Melatonin Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Long-acting Melatonin Receptor Agonists in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Long-acting Melatonin Receptor Agonists company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Melatonin Receptor Agonists revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting Melatonin Receptor Agonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ramelteon Major Player Table 3. Agomelatine Major Player Table 4. Other Major Player Table 5. Global Long-acting Melatonin Receptor Agonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Other Major Player Table 9. Long-acting Melatonin Receptor Agonists Industry Trends Table 10. Long-acting Melatonin Receptor Agonists Industry Drivers Table 11. Long-acting Melatonin Receptor Agonists Industry Opportunities and Challenges Table 12. Long-acting Melatonin Receptor Agonists Industry Restraints Table 13. Global Long-acting Melatonin Receptor Agonists Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Long-acting Melatonin Receptor Agonists Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Long-acting Melatonin Receptor Agonists Market Share by Region (2021-2026) Table 16. Global Long-acting Melatonin Receptor Agonists Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Long-acting Melatonin Receptor Agonists Market Share by Region (2027-2032) Table 18. Global Long-acting Melatonin Receptor Agonists Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Players (2021-2026) Table 20. Global Long-acting Melatonin Receptor Agonists Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Long-acting Melatonin Receptor Agonists Key Players Headquarters & Area Served Table 22. Global Long-acting Melatonin Receptor Agonists Players, Product Type & Application Table 23. Global Long-acting Melatonin Receptor Agonists Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Long-acting Melatonin Receptor Agonists by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Long-acting Melatonin Receptor Agonists Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Type (2021-2026) Table 30. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Type (2027-2032) Table 31. Global Long-acting Melatonin Receptor Agonists Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Application (2021-2026) Table 35. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Application (2027-2032) Table 36. Takeda Company Information Table 37. Takeda Business Overview Table 38. Takeda Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Long-acting Melatonin Receptor Agonists Product Portfolio Table 40. Takeda Recent Development Table 41. Sichuan Kelun Pharmaceuticals Company Information Table 42. Sichuan Kelun Pharmaceuticals Business Overview Table 43. Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 45. Sichuan Kelun Pharmaceuticals Recent Development Table 46. Sichuan Guowei Pharmaceuticals Company Information Table 47. Sichuan Guowei Pharmaceuticals Business Overview Table 48. Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 50. Sichuan Guowei Pharmaceuticals Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Long-acting Melatonin Receptor Agonists Product Portfolio Table 55. Novartis Recent Development Table 56. Jiangsu Hausen Pharmaceuticals Company Information Table 57. Jiangsu Hausen Pharmaceuticals Business Overview Table 58. Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 60. Jiangsu Hausen Pharmaceuticals Recent Development Table 61. Hangzhou Lingye Pharmaceutical Technology Company Information Table 62. Hangzhou Lingye Pharmaceutical Technology Business Overview Table 63. Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Product Portfolio Table 65. Hangzhou Lingye Pharmaceutical Technology Recent Development Table 66. Guangdong Annuo Pharmaceuticals Company Information Table 67. Guangdong Annuo Pharmaceuticals Business Overview Table 68. Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 70. Guangdong Annuo Pharmaceuticals Recent Development Table 71. Vanda Pharmaceuticals Company Information Table 72. Vanda Pharmaceuticals Business Overview Table 73. Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 75. Vanda Pharmaceuticals Recent Development Table 76. Servier Laboratories Company Information Table 77. Servier Laboratories Business Overview Table 78. Servier Laboratories Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Servier Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio Table 80. Servier Laboratories Recent Development Table 81. Rovi Pharma Company Information Table 82. Rovi Pharma Business Overview Table 83. Rovi Pharma Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Rovi Pharma Long-acting Melatonin Receptor Agonists Product Portfolio Table 85. Rovi Pharma Recent Development Table 86. Nectid Inc Company Information Table 87. Nectid Inc Business Overview Table 88. Nectid Inc Long-acting Melatonin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Nectid Inc Long-acting Melatonin Receptor Agonists Product Portfolio Table 90. Nectid Inc Recent Development Table 91. Dr Reddy's Laboratories Company Information Table 92. Dr Reddy's Laboratories Business Overview Table 93. Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio Table 95. Dr Reddy's Laboratories Recent Development Table 96. North America Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Long-acting Melatonin Receptor Agonists Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Long-acting Melatonin Receptor Agonists Revenue by Country (US$ Million) & (2027-2032) Table 110. China Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 111. China Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 112. China Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 113. China Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Long-acting Melatonin Receptor Agonists Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Long-acting Melatonin Receptor Agonists Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Long-acting Melatonin Receptor Agonists Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Long-acting Melatonin Receptor Agonists Image Figure 2. Global Long-acting Melatonin Receptor Agonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Melatonin Receptor Agonists Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ramelteon Image Figure 5. Agomelatine Image Figure 6. Other Image Figure 7. Global Long-acting Melatonin Receptor Agonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Long-acting Melatonin Receptor Agonists Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Other Image Figure 12. Global Long-acting Melatonin Receptor Agonists Market Size (US$ Million) & (2021-2032) Figure 13. Global Long-acting Melatonin Receptor Agonists Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Long-acting Melatonin Receptor Agonists Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Long-acting Melatonin Receptor Agonists Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Long-acting Melatonin Receptor Agonists Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Long-acting Melatonin Receptor Agonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Type (2021-2032) Figure 20. Global Long-acting Melatonin Receptor Agonists Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Application (2021-2032) Figure 23. North America Long-acting Melatonin Receptor Agonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032) Figure 25. North America Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032) Figure 26. North America Long-acting Melatonin Receptor Agonists Revenue Share by Country (2021-2032) Figure 27. United States Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Long-acting Melatonin Receptor Agonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032) Figure 32. Europe Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032) Figure 33. Europe Long-acting Melatonin Receptor Agonists Revenue Share by Country (2021-2032) Figure 34. Germany Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Long-acting Melatonin Receptor Agonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032) Figure 44. China Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032) Figure 45. Asia Long-acting Melatonin Receptor Agonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032) Figure 47. Asia Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032) Figure 48. Asia Long-acting Melatonin Receptor Agonists Revenue Share by Region (2021-2032) Figure 49. Japan Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Long-acting Melatonin Receptor Agonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032) Figure 57. SAMEA Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032) Figure 58. SAMEA Long-acting Melatonin Receptor Agonists Revenue Share by Country (2021-2032) Figure 59. Brazil Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Long-acting Melatonin Receptor Agonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Ramelteon
  • Agomelatine
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda
  • Sichuan Kelun Pharmaceuticals
  • Sichuan Guowei Pharmaceuticals
  • Novartis
  • Jiangsu Hausen Pharmaceuticals
  • Hangzhou Lingye Pharmaceutical Technology
  • Guangdong Annuo Pharmaceuticals
  • Vanda Pharmaceuticals
  • Servier Laboratories
  • Rovi Pharma
  • Nectid Inc
  • Dr Reddy's Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting Melatonin Receptor Agonists Market by Type
  3. 1.2.1 Global Long-acting Melatonin Receptor Agonists Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ramelteon
  5. 1.2.3 Agomelatine
  6. 1.2.4 Other
  7. 1.3 Long-acting Melatonin Receptor Agonists Market by Application
  8. 1.3.1 Global Long-acting Melatonin Receptor Agonists Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Long-acting Melatonin Receptor Agonists Market Dynamics
  1. 2.1 Long-acting Melatonin Receptor Agonists Industry Trends
  2. 2.2 Long-acting Melatonin Receptor Agonists Industry Drivers
  3. 2.3 Long-acting Melatonin Receptor Agonists Industry Opportunities and Challenges
  4. 2.4 Long-acting Melatonin Receptor Agonists Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Long-acting Melatonin Receptor Agonists Market Perspective (2021-2032)
  2. 3.2 Global Long-acting Melatonin Receptor Agonists Growth Trends by Region
  3. 3.2.1 Global Long-acting Melatonin Receptor Agonists Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting Melatonin Receptor Agonists Market Size by Region (2021-2026)
  5. 3.2.3 Global Long-acting Melatonin Receptor Agonists Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Long-acting Melatonin Receptor Agonists Revenue by Players
  2. 4.1.1 Global Long-acting Melatonin Receptor Agonists Revenue by Players (2021-2026)
  3. 4.1.2 Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Long-acting Melatonin Receptor Agonists Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting Melatonin Receptor Agonists Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Long-acting Melatonin Receptor Agonists Key Players Headquarters & Area Served
  7. 4.4 Global Long-acting Melatonin Receptor Agonists Players, Product Type & Application
  8. 4.5 Global Long-acting Melatonin Receptor Agonists Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Long-acting Melatonin Receptor Agonists Market CR5 and HHI
  11. 4.6.3 2025 Long-acting Melatonin Receptor Agonists Tier 1, Tier 2, and Tier 3
5 Long-acting Melatonin Receptor Agonists Market Size by Type
  1. 5.1 Global Long-acting Melatonin Receptor Agonists Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2032)
  3. 5.3 Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Type (2021-2032)
6 Long-acting Melatonin Receptor Agonists Market Size by Application
  1. 6.1 Global Long-acting Melatonin Receptor Agonists Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2032)
  3. 6.3 Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Long-acting Melatonin Receptor Agonists Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Sichuan Kelun Pharmaceuticals
  8. 7.2.1 Sichuan Kelun Pharmaceuticals Company Information
  9. 7.2.2 Sichuan Kelun Pharmaceuticals Business Overview
  10. 7.2.3 Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  12. 7.2.5 Sichuan Kelun Pharmaceuticals Recent Developments
  13. 7.3 Sichuan Guowei Pharmaceuticals
  14. 7.3.1 Sichuan Guowei Pharmaceuticals Company Information
  15. 7.3.2 Sichuan Guowei Pharmaceuticals Business Overview
  16. 7.3.3 Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  18. 7.3.5 Sichuan Guowei Pharmaceuticals Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Long-acting Melatonin Receptor Agonists Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Jiangsu Hausen Pharmaceuticals
  26. 7.5.1 Jiangsu Hausen Pharmaceuticals Company Information
  27. 7.5.2 Jiangsu Hausen Pharmaceuticals Business Overview
  28. 7.5.3 Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  30. 7.5.5 Jiangsu Hausen Pharmaceuticals Recent Developments
  31. 7.6 Hangzhou Lingye Pharmaceutical Technology
  32. 7.6.1 Hangzhou Lingye Pharmaceutical Technology Company Information
  33. 7.6.2 Hangzhou Lingye Pharmaceutical Technology Business Overview
  34. 7.6.3 Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Product Portfolio
  36. 7.6.5 Hangzhou Lingye Pharmaceutical Technology Recent Developments
  37. 7.7 Guangdong Annuo Pharmaceuticals
  38. 7.7.1 Guangdong Annuo Pharmaceuticals Company Information
  39. 7.7.2 Guangdong Annuo Pharmaceuticals Business Overview
  40. 7.7.3 Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  42. 7.7.5 Guangdong Annuo Pharmaceuticals Recent Developments
  43. 7.8 Vanda Pharmaceuticals
  44. 7.8.1 Vanda Pharmaceuticals Company Information
  45. 7.8.2 Vanda Pharmaceuticals Business Overview
  46. 7.8.3 Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  48. 7.8.5 Vanda Pharmaceuticals Recent Developments
  49. 7.9 Servier Laboratories
  50. 7.9.1 Servier Laboratories Company Information
  51. 7.9.2 Servier Laboratories Business Overview
  52. 7.9.3 Servier Laboratories Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Servier Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio
  54. 7.9.5 Servier Laboratories Recent Developments
  55. 7.10 Rovi Pharma
  56. 7.10.1 Rovi Pharma Company Information
  57. 7.10.2 Rovi Pharma Business Overview
  58. 7.10.3 Rovi Pharma Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Rovi Pharma Long-acting Melatonin Receptor Agonists Product Portfolio
  60. 7.10.5 Rovi Pharma Recent Developments
  61. 7.11 Nectid Inc
  62. 7.11.1 Nectid Inc Company Information
  63. 7.11.2 Nectid Inc Business Overview
  64. 7.11.3 Nectid Inc Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Nectid Inc Long-acting Melatonin Receptor Agonists Product Portfolio
  66. 7.11.5 Nectid Inc Recent Developments
  67. 7.12 Dr Reddy's Laboratories
  68. 7.12.1 Dr Reddy's Laboratories Company Information
  69. 7.12.2 Dr Reddy's Laboratories Business Overview
  70. 7.12.3 Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio
  72. 7.12.5 Dr Reddy's Laboratories Recent Developments
8 North America
  1. 8.1 North America Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
  2. 8.2 North America Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2032)
  3. 8.2.1 North America Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026)
  4. 8.2.2 North America Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032)
  5. 8.3 North America Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032)
  6. 8.4 North America Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2032)
  7. 8.4.1 North America Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026)
  8. 8.4.2 North America Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032)
  9. 8.5 North America Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032)
  10. 8.6 North America Long-acting Melatonin Receptor Agonists Revenue by Country
  11. 8.6.1 North America Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026)
  13. 8.6.3 North America Long-acting Melatonin Receptor Agonists Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
  2. 9.2 Europe Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2032)
  3. 9.2.1 Europe Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026)
  4. 9.2.2 Europe Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032)
  5. 9.3 Europe Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032)
  6. 9.4 Europe Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2032)
  7. 9.4.1 Europe Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026)
  8. 9.4.2 Europe Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032)
  9. 9.5 Europe Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032)
  10. 9.6 Europe Long-acting Melatonin Receptor Agonists Revenue by Country
  11. 9.6.1 Europe Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026)
  13. 9.6.3 Europe Long-acting Melatonin Receptor Agonists Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
  2. 10.2 China Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2032)
  3. 10.2.1 China Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026)
  4. 10.2.2 China Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032)
  5. 10.3 China Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032)
  6. 10.4 China Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2032)
  7. 10.4.1 China Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026)
  8. 10.4.2 China Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032)
  9. 10.5 China Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
  2. 11.2 Asia Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2032)
  3. 11.2.1 Asia Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026)
  4. 11.2.2 Asia Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032)
  5. 11.3 Asia Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032)
  6. 11.4 Asia Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2032)
  7. 11.4.1 Asia Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026)
  8. 11.4.2 Asia Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032)
  9. 11.5 Asia Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032)
  10. 11.6 Asia Long-acting Melatonin Receptor Agonists Revenue by Country
  11. 11.6.1 Asia Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026)
  13. 11.6.3 Asia Long-acting Melatonin Receptor Agonists Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
  2. 12.2 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Type (2027-2032)
  5. 12.3 SAMEA Long-acting Melatonin Receptor Agonists Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Application (2027-2032)
  9. 12.5 SAMEA Long-acting Melatonin Receptor Agonists Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country
  11. 12.6.1 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Long-acting Melatonin Receptor Agonists Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst